A study of immune changes after glioblastoma surgery and treatment
Original title: Impact of Fluorescence-Guided Resection and Chemoradiotherapy on the Systemic Immune Response in Glioblastoma: A Kinetic Analysis of Immune Biomarkers.
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
No phase is listed, so treat this as an early study in people.
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study looks at how the body's immune system changes after brain tumor surgery and treatment.
Who this trial is for. This study is for people with glioblastoma: A glioma that is given grade 4, the highest grade. It grows fast. Treatment usually starts soon after it is found. It often means surgery, then radiation and chemotherapy. See the glossary having surgery guided by a glowing dye. It checks their blood after chemo and radiation to track immune changes.
Where it stands. This trial has not reported results. It is measuring immune cells and signals in the blood over time. Those answers are not in yet.
What this means, and what it doesn't
What it could mean: The blood results may help doctors learn how these treatments change the immune system. Someone who fits could ask their care team about this study.
What it doesn't mean: This does not mean a new treatment works. A trial is a test, not proven care. Joining one is not a promise of benefit. It is not a cure.
Source: ClinicalTrials.gov, September 24, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.